Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions
about
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazoleFlucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalIntegrated therapy for HIV and cryptococcosisIncreased permeability of blood-brain barrier is mediated by serine protease during Cryptococcus meningitisA prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, MalawiChemical Inhibitors of Non-Homologous End Joining Increase Targeted Construct Integration in Cryptococcus neoformansCapsule independent uptake of the fungal pathogen Cryptococcus neoformans into brain microvascular endothelial cellsSiderophores; iron scavengers: the novel & promising targets for pathogen specific antifungal therapy.Low CD4 count plus coma predicts cryptococcal meningitis in TanzaniaNeuromeningeal cryptococcosis in sub-Saharan Africa: Killer disease with sparse dataCombination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in MalawiCryptococcal meningitis: epidemiology and therapeutic options.Clinical pharmacokinetics of oral controlled-release 5-fluorocytosineMolecular diagnosis of central nervous system opportunistic infections in HIV-infected Zambian adults.Antifungal drug discovery through the study of invertebrate model hosts.Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.Predictors of bacterial meningitis in resource-limited contexts: an Angolan case.Resistance to antifungals that target CYP51.Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens.An update on Cryptococcus among HIV-infected patients.Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.Massive cerebral edema resulting in brain death as a complication of Cryptococcus neoformans meningitis.Combination Versus Monotherapy for the Treatment of HIV Associated Cryptococcal MeningitisComparative effectiveness of induction therapy for human immunodeficiency virus-associated cryptococcal meningitis: a network meta-analysis.The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis.Antibiotic treatment for bacterial meningitis in children in developing countries.Management of cryptococcal meningitis in a district hospital in KwaZulu-Natal: a clinical auditThe Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier.Central Nervous System Cryptococcosis among a Cohort of HIV Infected Patients from a University Hospital of North India.Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.A Retrospective Cohort Study of Lesion Distribution of HIV-1 Infection Patients With Cryptococcal Meningoencephalitis on MRI: Correlation With Immunity and Immune Reconstitution.The prevalence, clinical features, risk factors and outcome associated with cryptococcal meningitis in HIV positive patients in Kenya.HIV and co-infections.Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy.Predictors of outcome in routine care for Cryptococcal meningitis in Western Kenya: lessons for HIV outpatient care in resource-limited settings.Epidemiology and management of cryptococcal meningitis: developments and challenges.New Insights into HIV/AIDS-Associated Cryptococcosis.The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in KenyaAsymptomatic cryptococcemia in resource-limited settings.
P2860
Q24678763-EC623E27-9A0E-4B01-8610-ACC736AB39D9Q27012487-3F902CD9-B120-4F7D-BACC-A43D712B4459Q28077707-8C8DCF56-81AD-44F3-85D8-898483C29F9FQ28305427-2C50D795-60C9-4CAE-9D9B-914839C46E0AQ28534417-ACC8B1C2-61FD-41EA-BBAA-6E3E7C74AB03Q28554238-7DE23DD1-088C-4281-9A8B-5BC814140B1EQ28730545-5DF0CC04-E9D3-4788-A921-AD18D8A76D75Q30243906-677AEADF-B518-4494-90C8-A5780ACA87F4Q30444984-63B40F42-B265-4A53-A8F0-2023C67A95AAQ30934853-388D559F-3297-4D8A-8875-8FB103DF74E0Q33588561-88084F9A-F9A5-4D21-8A11-D6103DD18846Q33633343-6F6B9D12-F9E9-4488-9BFC-C21276241EA3Q33676182-407522E2-4978-4DB3-8570-18F5C72AFE4DQ33678132-6C400E16-8F4E-404B-9A7F-3064D0BC273DQ34002069-5EEDA090-AEB3-4D76-9237-D215E1087CD2Q34020746-1425F109-43CF-4C48-A5B2-1F693107FBD0Q34047089-EDCE9E86-A964-4FB4-B3B0-FF37470BB636Q34276700-BD6A0396-A84A-48C9-8883-6615A413975AQ34459194-602D6377-5BFF-4C1F-8A16-E728A97B7F6DQ34625655-0202C301-5D09-4FD1-9FF1-7FCE8C7191D2Q34874626-228D2402-DAAA-4BBF-8C67-E21114C4C058Q35054798-C8B2FF68-17BC-4588-AB12-875A6CFC9DACQ35230534-A909F010-6051-4329-9605-4A40EB548882Q35628245-5FC01791-36C6-4032-AA32-D3743B524AC4Q35635476-B707CE10-A0FD-438B-A885-320F326495EEQ35635850-42E7F23C-BDD6-47AC-9C6E-E8BD170F2DAAQ35853546-6AEB44CA-5F6F-49D9-801A-DCC63C4EFAF2Q36012849-EEDBDA66-A609-4608-BBB8-C9382276A21CQ36236518-31F44688-FF5D-4514-A5BE-D2902BB0A4D6Q36318103-7FB628CF-EC46-4F86-88DF-F49C24C42D4BQ36489747-A555E300-B1BC-4BD0-900A-3E6FBD9C802EQ36580897-36EA567B-E082-4997-8F9F-7D68A43DD372Q36700649-F8D2979A-4091-403D-8F95-16C0470A898DQ36970184-A8A0149D-CB5B-4C47-B804-4321F5C92BE6Q36996124-2B4FF541-467C-4CD9-B3E2-7E9278EE6403Q37043583-F8E0BD2B-09A4-432A-AD88-B4BA3E1C087DQ37098995-CA3180BF-585E-4405-A4CD-540C69A5CC52Q37156556-E1B34F0D-DEA3-4120-8ADF-C0584327F163Q37259604-CADF691C-1B7E-481F-BAC5-EFCCA49D7565Q37259640-AFA72662-1D47-4909-9E0C-5324DF45599B
P2860
Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Clinical presentation, natural ...... treated under local conditions
@ast
Clinical presentation, natural ...... treated under local conditions
@en
Clinical presentation, natural ...... treated under local conditions
@nl
type
label
Clinical presentation, natural ...... treated under local conditions
@ast
Clinical presentation, natural ...... treated under local conditions
@en
Clinical presentation, natural ...... treated under local conditions
@nl
prefLabel
Clinical presentation, natural ...... treated under local conditions
@ast
Clinical presentation, natural ...... treated under local conditions
@en
Clinical presentation, natural ...... treated under local conditions
@nl
P2093
P2860
P921
P3181
P356
P1476
Clinical presentation, natural ...... treated under local conditions
@en
P2093
P2860
P304
P3181
P356
10.1136/PMJ.77.914.769
P407
P577
2001-12-01T00:00:00Z